GlaxoSmithKline’s diabetes drug Avandia (rosiglitazone) has failed to show it can significantly reduce atherosclerosis in patients with type 2 diabetes.

More than half of Americans with chronic illnesses did not fill prescriptions, skipped doses of their medications, or didn’t see a doctor for a medical problem because they could not afford to, a new study showed.

While we are waiting for a once a day and once a week injectable GLP-1(exentide-4), Oramed Pharmaceuticals presented the results of a once a day oral administration of exenatide-4. 

A new observational study finds an association between higher levels of nonfasting triglycerides and increasing risk for ischemic stroke.

President-elect Barack Obama’s plans to overhaul the U.S. health care system would cost the federal government $75 billion but would provide health insurance for 95 percent of Americans.

Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced positive results from a Phase 1a clinical trial of MBX-2982.

The Endocrine Society has released a new clinical practice guideline for the primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk.

Aspirin therapy is commonly used for primary prevention of cardiovascular events in persons with type 2 diabetes, but a Japanese study of 2,539 subjects found no statistically significant reduction in the primary end point of total atherosclerotic events, except in patients aged at least 65 years.

Every week I see a list of drugs that are going to be available generically but some of them never seem to appear. Elizabeth Brule, PharmD Candidate, University of Florida College of Pharmacy, has done some research as to why that occurs and if you take the time to read …

It’s when blood sugar levels are rising, but disease can still be prevented, CDC says. With over 25% of Americans with pre-diabetes, only 4% are aware they have pre-diabetes.